| Document |
Document Title |
|
JP5873487B2 |
Provided is a compound having a monoamine reuptake inhibitory activity, which is represented by the formula (I) wherein ring A is an optionally substituted 6-membered aromatic ring, ring B is the substituents on ring A are optionally bon...
|
|
JP5823503B2 |
This invention relates to compounds of the formula wherein A, B and R1 to R7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as medicaments for th...
|
|
JP5782586B2 |
Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especia...
|
|
JP2015145401A |
To provide compounds for medicament to inhibit histone deacetylase.This invention provides a compound such as phenyl hydroxamic acid substituted with a group comprising, for example, oxazepine, diazepine, thiazepine skeletons, pyrimidine...
|
|
JP5763621B2 |
Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug re...
|
|
JP5723522B2 |
Provided are a novel organic electroluminescent compound and an organic electroluminescent device using the same as an electroluminescent material. The disclosed organic electroluminescent compound is represented by Chemical Formula 1: w...
|
|
JP2015507622A |
Compounds of formula (I) (where m, n, A, X1, X2, X3, X4, R1, R2, R3a, R3b, R4a, and R4b are as defined herein). Or its pharmaceutically acceptable salt. Also disclosed are methods of making the compounds and using the compounds for the t...
|
|
JP2015501788A |
The present invention is useful in methods of treating and alleviating heart, brain, kidney, immune, and reproductive system diseases and disorders resulting from ischemia or post-ischemia reperfusion and any downstream complications ass...
|
|
JP5602641B2 |
An N-acyl anthranilic acid derivative represented by general formula (1) or a salt thereof is useful for prevention or treatment of diseases associated with excessive production of collagen. (In the formula, R 1 represents a carboxyl gro...
|
|
JP5597689B2 |
A compound comprising a substituent of the formula (II) is disclosed as an HIV protease inhibitor. Intermediates for making such compounds and processes for making such intermediates are also disclosed.
|
|
JP2014177468A |
To provide a compound treating gram-negative infections by inhibiting activity of an enzyme uridyldiphospho-3-O-(R-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC), which is the enzyme in the first committed step in the synthesis ...
|
|
JP5583406B2 |
This invention relates to five specific N-hydroxybenzamide compounds for the inhibition of histone deacetylase: N-hydroxy-4-(5-(p-tolyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)
benzamide; N-hydroxy-4-(5-(3-methoxyphenyl)-2,5-diazabicyclo[2.2...
|
|
JP5563807B2 |
|
|
JP2014513145A |
The present invention relates to benzazepine derivatives of the formula (I) or a physiologically tolerated salt thereof. The present invention also relates to pharmaceutical compositions comprising such benzazepine derivatives, and the u...
|
|
JP5497429B2 |
Compounds represented by the general formula (I): wherein each symbol is as defined in the description [with the proviso that 9-chloro-7-(1,1-dimethylethyl)-2,3,4,5-tetrahydro-1,4-benz-o
xazepine and N-[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-...
|
|
JP2014511355A |
Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
|
|
JP2014510120A |
The present invention relates to 1,4 Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active com...
|
|
JP2014508751A |
This invention relates to compounds of the formula wherein and R1 to R3 are as described herein, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as pharmaceuticals for th...
|
|
JP5468900B2 |
The present invention relates to novel aniline derivatives and their use in therapy, in particular their use in the treatment of fungal infections.
|
|
JP2014508182A |
The present invention relates to 1,4-Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active com...
|
|
JP2014503504A |
The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other act...
|
|
JP5392917B2 |
This invention provides a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted lower alkyl, Y is -S(O)n- wherein n is 1 or 2, or -CO-, R 2 is hydrogen or lower alkyl, R...
|
|
JP5385299B2 |
The present invention is related to novel tricyclic compounds of formula (I) having TRPA1 receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their u...
|
|
JPWO2012008435A1 |
The present invention relates to a novel biarylamide derivative represented by the following formula (1), which has an affinity for the aldosterone receptor, or a pharmacologically acceptable salt thereof. [In the formula, A is any group...
|
|
JP2013166750A |
To provide a pharmaceutical made of a novel biaryl amide derivative having affinity to an aldosterone receptor or its pharmacologically acceptable salt.A pharmaceutical is made of a compound represented by formula (1) or its pharmacologi...
|
|
JP5261275B2 |
The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a co...
|
|
JP5264160B2 |
A compound comprising a substituent of the formula (II) is disclosed as an HIV protease inhibitor. Intermediates for making such compounds and processes for making such intermediates are also disclosed.
|
|
JP2013512272A |
Compounds of the formula I: wherein m, n, X1, X2, Y1, Y2, R1 and R2 are as defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
|
|
JP5175316B2 |
Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparati...
|
|
JP5175742B2 |
The invention is drawn to novel macrolide compounds of formula I having antibiotic and antineoplastic activities, useful as medicaments and/or agrochemicals for microorganism infections, in particularly for infectious diseases involving ...
|
|
JP5069392B2 |
There are provided according to the invention, novel compounds of formula (I) wherein R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, X, a, b and Z are as defined in the specification, processes for preparing them, formulations containing them and t...
|
|
JP5049129B2 |
The invention relates to novel compounds and methods of using them for modulating sleep.
|
|
JP2012193183A |
To develop novel analogues of F152.The present invention relates to: compounds having the following formula (I); methods for synthesizing them; and methods for the use thereof in the treatment of various disorders including inflammatory ...
|
|
JP5025980B2 |
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds...
|
|
JP5001227B2 |
The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA anal...
|
|
JP4979590B2 |
The invention relates to compounds of the formula I wherein R, R1, R2, R3, X, and n are defined in the specification. The invention also provides pharmaceutically suitable acid addition salts thereof and all forms of optically pure enant...
|
|
JP2012131813A |
To provide a substituted benzimidazole compound which is useful as an anti-infective agent lowering the tolerability, toxicity or growth of microorganisms.The compound is represented by formula (Va), wherein R1 is OH, OCOCO2H or substitu...
|
|
JP2012514655A |
Fluorinated compounds and methods of making fluorinated compounds are described herein.
|
|
JP4949413B2 |
The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters the...
|
|
JP4936512B2 |
|
|
JP2012511008A |
The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compoun...
|
|
JP4926058B2 |
The present invention relates to compounds with vasopressin V1a antagonist activity and to pharmaceutical compositions comprising such compounds. The present invention also relates to the use of vasopressin V1a antagonists for the treatm...
|
|
JP4912887B2 |
New derivatives of FK 506 are disclosed. These new derivatives and other derivatives that are useful for determining the levels of FK 506 in a sample are also provided as are assay procedures and kits for use in determining the levels of...
|
|
JP4891396B2 |
The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, h...
|
|
JP2011201778A |
To provide a compound that modulates the function of TRPV1 receptor, a TRPV1 receptor modulator comprising the derivative as an active ingredient, and an agent for preventing or treating a disease involving TRPV1 receptor, such as pain.T...
|
|
JP2011190238A |
To provide a novel cyclic squaric acid amide derivative or a salt thereof, and a prophylactic and/or therapeutic agent comprising at least one thereof as an active ingredient, which is particularly used for diseases against which a calci...
|
|
JP4769192B2 |
Novel inhibitors of cathepsin S, K, B, and L, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
|
|
JP4743382B2 |
A medicament having inhibitory activity against NF- kappa B activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacolo...
|
|
JP2011522807A |
Novel terpenes and macrocycles are activators of TGR5 and can be used for the prevention and/or treatment of Diabetes Type 2, obesity, neuropathy and/or nephropathy.
|
|
JP4694747B2 |
Compounds according to general formula (1), and pharmaceutically acceptable salts thereof, wherein V is a covalent bond or NH, X is selected from CH2, O and N-alkyl, Z is either S or -CH=CH-, R<1 >and R<2 >are independently selected from...
|
